{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:08:39Z","timestamp":1783908519102,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:00:00Z","timestamp":1775865600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100016714","name":"University of Sharjah","doi-asserted-by":"publisher","award":["23010902135"],"award-info":[{"award-number":["23010902135"]}],"id":[{"id":"10.13039\/100016714","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05214-y","type":"journal-article","created":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T03:14:03Z","timestamp":1775877243000},"page":"14177-14189","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of TLR4\/TRAF6\/NF-\u03baB pathway by empagliflozin mitigates concanavalin A-induced autoimmune hepatitis in mice"],"prefix":"10.1007","volume":"399","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0021-5533","authenticated-orcid":false,"given":"Dalia H.","family":"El-Kashef","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noha O.","family":"Shawky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Mahdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitham M.","family":"Sewilam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed A.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,11]]},"reference":[{"key":"5214_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117908","volume":"256","author":"AM Abdelhamid","year":"2020","unstructured":"Abdelhamid AM, Elsheakh AR, Abdelaziz RR, Suddek GM (2020) Empagliflozin ameliorates ethanol-induced liver injury by modulating NF-\u03baB\/Nrf-2\/PPAR-\u03b3 interplay in mice. Life Sci 256:117908","journal-title":"Life Sci"},{"key":"5214_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111624","volume":"139","author":"AS Ahmed","year":"2021","unstructured":"Ahmed AS, Mona MM, Abdel-Kareem MA, Elsisy RA (2021) SGLT2 inhibitor empagliflozin monotherapy alleviates renal oxidative stress in albino Wistar diabetic rats after myocardial infarction induction. Biomed Pharmacother 139:111624","journal-title":"Biomed Pharmacother"},{"key":"5214_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.01077","volume":"8","author":"I Andreadou","year":"2017","unstructured":"Andreadou I, Efentakis P, Balafas E, Togliatto G, Davos CH, Varela A, Dimitriou CA, Nikolaou PE, Maratou E, Lambadiari V, Ikonomidis I, Kostomitsopoulos N, Brizzi MF, Dimitriadis G, Iliodromitis EK (2017) Empagliflozin limits myocardial infarction in vivo and cell death in vitro: role of STAT3, mitochondria, and redox aspects. Front Physiol 8:1077","journal-title":"Front Physiol"},{"key":"5214_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02014","volume":"10","author":"L Barbier","year":"2019","unstructured":"Barbier L, Ferhat M, Salam\u00e9 E, Robin A, Herbelin A, Gombert JM, Silvain C, Barbarin A (2019) Interleukin-1 family cytokines: keystones in liver inflammatory diseases. Front Immunol 10:2014","journal-title":"Front Immunol"},{"key":"5214_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.716469","volume":"12","author":"L Barnabei","year":"2021","unstructured":"Barnabei L, Laplantine E, Mbongo W, Rieux-Laucat F, Weil R (2021) NF-\u03baB: at the borders of autoimmunity and inflammation. Front Immunol 12:716469","journal-title":"Front Immunol"},{"key":"5214_CR6","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","volume":"72","author":"MM Bradford","year":"1976","unstructured":"Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248\u2013254","journal-title":"Anal Biochem"},{"key":"5214_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005875","volume":"12","author":"J Butler","year":"2019","unstructured":"Butler J, Zannad F, Fitchett D, Zinman B, Koitka-Weber A, Von Eynatten M, Zwiener I, George J, Brueckmann M, Cheung AK, Wanner C (2019) Empagliflozin improves kidney outcomes in patients with or without heart failure. Circ Heart Fail 12:e005875","journal-title":"Circ Heart Fail"},{"key":"5214_CR8","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.3748\/wjg.v20.i10.2515","volume":"20","author":"AJ Czaja","year":"2014","unstructured":"Czaja AJ (2014) Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 20:2515\u20132532","journal-title":"World J Gastroenterol"},{"key":"5214_CR9","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1111\/jphp.12651","volume":"68","author":"DS El-Agamy","year":"2016","unstructured":"El-Agamy DS (2016) Pirfenidone ameliorates concanavalin A-induced hepatitis in mice via modulation of reactive oxygen species\/nuclear factor kappa B signalling pathways. J Pharm Pharmacol 68:1559\u20131566","journal-title":"J Pharm Pharmacol"},{"key":"5214_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00292","volume":"9","author":"DS El-Agamy","year":"2018","unstructured":"El-Agamy DS, Shaaban AA, Almaramhy HH, Elkablawy S, Elkablawy MA (2018) Pristimerin as a novel hepatoprotective agent against experimental autoimmune hepatitis. Front Pharmacol 9:292","journal-title":"Front Pharmacol"},{"key":"5214_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.114931","volume":"393","author":"DH El-Kashef","year":"2020","unstructured":"El-Kashef DH, Abdelrahman RS (2020) Montelukast ameliorates concanavalin A-induced autoimmune hepatitis in mice via inhibiting TNF-\u03b1\/JNK signaling pathway. Toxicol Appl Pharmacol 393:114931","journal-title":"Toxicol Appl Pharmacol"},{"key":"5214_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109494","volume":"114","author":"DH El-Kashef","year":"2023","unstructured":"El-Kashef DH, Sewilam HM (2023) Empagliflozin mitigates methotrexate-induced hepatotoxicity: targeting ASK-1\/JNK\/Caspase-3 pathway. Int Immunopharmacol 114:109494","journal-title":"Int Immunopharmacol"},{"key":"5214_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","volume":"82","author":"GL Ellman","year":"1959","unstructured":"Ellman GL (1959) Tissue sulfhydryl groups. Arch Biochem Biophys 82:70\u201377","journal-title":"Arch Biochem Biophys"},{"key":"5214_CR14","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1007\/s10787-022-01058-z","volume":"30","author":"M Elshal","year":"2022","unstructured":"Elshal M, Hazem SH (2022) Escin suppresses immune cell infiltration and selectively modulates Nrf2\/HO-1, TNF-\u03b1\/JNK, and IL-22\/STAT3 signaling pathways in concanavalin A-induced autoimmune hepatitis in mice. Inflammopharmacology 30:2317\u20132329","journal-title":"Inflammopharmacology"},{"key":"5214_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-022-00951-5","volume":"14","author":"S Gohari","year":"2022","unstructured":"Gohari S, Reshadmanesh T, Khodabandehloo H, Karbalaee-Hasani A, Ahangar H, Arsang-Jang S, Ismail-Beigi F, Dadashi M, Ghanbari S, Taheri H, Fathi M, Muhammadi MJ, Mahmoodian R, Asgari A, Tayaranian M, Moharrami M, Mahjani M, Ghobadian B, Chiti H, Gohari S (2022) The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and coronary artery disease: the EMPA-CARD randomized controlled trial. Diabetol Metab Syndr 14:170","journal-title":"Diabetol Metab Syndr"},{"key":"5214_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/1755-1536-3-21","volume":"3","author":"J Guo","year":"2010","unstructured":"Guo J, Friedman SL (2010) Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair 3:21","journal-title":"Fibrogenesis Tissue Repair"},{"key":"5214_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/cells11193107","author":"M Heimke","year":"2022","unstructured":"Heimke M, Lenz F, Rickert U, Lucius R, Cossais F (2022) Anti-inflammatory properties of the SGLT2 inhibitor empagliflozin in activated primary microglia. Cells. https:\/\/doi.org\/10.3390\/cells11193107","journal-title":"Cells"},{"key":"5214_CR18","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1007\/s10787-023-01327-5","volume":"31","author":"KM Ibrahim","year":"2023","unstructured":"Ibrahim KM, Ahmed HI, Ramadan L, Balah A (2023) A low dose of naloxone mitigates autoimmune hepatitis by regulating TLR4\/NF-\u03baB and Nrf2\/HO-1 signaling pathways. Inflammopharmacology 31:2467\u20132478","journal-title":"Inflammopharmacology"},{"key":"5214_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104870","volume":"158","author":"CN Koyani","year":"2020","unstructured":"Koyani CN, Plastira I, Sourij H, Hallstr\u00f6m S, Schmidt A, Rainer PP, Bugger H, Frank S, Malle E, VON Lewinski D (2020) Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacol Res 158:104870","journal-title":"Pharmacol Res"},{"key":"5214_CR20","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1002\/cld.653","volume":"10","author":"M Krishna","year":"2017","unstructured":"Krishna M (2017) Patterns of necrosis in liver disease. Clin Liver Dis 10:53\u201356","journal-title":"Clin Liver Dis"},{"key":"5214_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0745-5","volume":"17","author":"S Lahnwong","year":"2018","unstructured":"Lahnwong S, Chattipakorn SC, Chattipakorn N (2018) Potential mechanisms responsible for cardioprotective effects of sodium-glucose co-transporter 2 inhibitors. Cardiovasc Diabetol 17:101","journal-title":"Cardiovasc Diabetol"},{"key":"5214_CR22","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/cld.798","volume":"14","author":"C Lammert","year":"2019","unstructured":"Lammert C (2019) Genetic and environmental risk factors for autoimmune hepatitis. Clin Liver Dis 14:29\u201332","journal-title":"Clin Liver Dis"},{"key":"5214_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9944880","volume":"2021","author":"N Lee","year":"2021","unstructured":"Lee N, Heo YJ, Choi SE, Jeon JY, Han SJ, Kim DJ, Kang Y, Lee KW, Kim HJ (2021) Anti-inflammatory effects of empagliflozin and gemigliptin on LPS-stimulated macrophage via the IKK\/NF-\u03baB, MKK7\/JNK, and JAK2\/STAT1 signalling pathways. J Immunol Res 2021:9944880","journal-title":"J Immunol Res"},{"key":"5214_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0816-2","volume":"18","author":"C Li","year":"2019","unstructured":"Li C, Zhang J, Xue M, Li X, Han F, Liu X, Xu L, Lu Y, Cheng Y, Li T, Yu X, Sun B, Chen L (2019) SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart. Cardiovasc Diabetol 18:15","journal-title":"Cardiovasc Diabetol"},{"key":"5214_CR25","first-page":"7","volume":"66","author":"H Louis","year":"2003","unstructured":"Louis H, Le Moine O, Goldman M, Devi\u00e8re J (2003) Modulation of liver injury by interleukin-10. Acta Gastroenterol Belg 66:7\u201314","journal-title":"Acta Gastroenterol Belg"},{"key":"5214_CR26","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2016.10.36","volume":"4","author":"RJ Macisaac","year":"2016","unstructured":"Macisaac RJ, Jerums G, Ekinci EI (2016) Cardio-renal protection with empagliflozin. Ann Transl Med 4:409","journal-title":"Ann Transl Med"},{"key":"5214_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","volume":"95","author":"H Ohkawa","year":"1979","unstructured":"Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351\u2013358","journal-title":"Anal Biochem"},{"key":"5214_CR28","volume":"81","author":"A Shafiq","year":"2022","unstructured":"Shafiq A, Mahboob E, Samad MA, Ur Rehman MH, Tharwani ZH (2022) The dual role of empagliflozin: cardio renal protection in T2DM patients. Ann Med Surg (Lond) 81:104555","journal-title":"Ann Med Surg (Lond)"},{"key":"5214_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.108088","volume":"100","author":"MH Sharawy","year":"2021","unstructured":"Sharawy MH, El-Kashef DH, Shaaban AA, El-Agamy DS (2021) Anti-fibrotic activity of sitagliptin against concanavalin A-induced hepatic fibrosis. Role of Nrf2 activation\/NF-\u03baB inhibition. Int Immunopharmacol 100:108088","journal-title":"Int Immunopharmacol"},{"key":"5214_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.taap.2009.11.005","volume":"242","author":"JY Shim","year":"2010","unstructured":"Shim JY, Kim MH, Kim HD, Ahn JY, Yun YS, Song JY (2010) Protective action of the immunomodulator ginsan against carbon tetrachloride-induced liver injury via control of oxidative stress and the inflammatory response. Toxicol Appl Pharmacol 242:318\u2013325","journal-title":"Toxicol Appl Pharmacol"},{"key":"5214_CR31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s10620-009-0732-5","volume":"55","author":"H Shirin","year":"2010","unstructured":"Shirin H, Aeed H, Alin A, Matas Z, Kirchner M, Brazowski E, Goldiner I, Bruck R (2010) Inhibition of immune-mediated concanavalin a-induced liver damage by free-radical scavengers. Dig Dis Sci 55:268\u2013275","journal-title":"Dig Dis Sci"},{"key":"5214_CR32","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9437043","volume":"2019","author":"E Sucher","year":"2019","unstructured":"Sucher E, Sucher R, Gradistanac T, Brandacher G, Schneeberger S, Berg T (2019) Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies. J Immunol Res 2019:9437043","journal-title":"J Immunol Res"},{"key":"5214_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.4254\/wjh.v12.i7.332","volume":"12","author":"HK Tan","year":"2020","unstructured":"Tan HK, Yates E, Lilly K, Dhanda AD (2020) Oxidative stress in alcohol-related liver disease. World J Hepatol 12:332\u2013349","journal-title":"World J Hepatol"},{"key":"5214_CR34","doi-asserted-by":"publisher","first-page":"865","DOI":"10.33594\/000000178","volume":"53","author":"L Uthman","year":"2019","unstructured":"Uthman L, Homayr A, Juni RP, Spin EL, Kerindongo R, Boomsma M, Hollmann MW, Preckel B, Koolwijk P, Van Hinsbergh VWM, Zuurbier CJ, Albrecht M, Weber NC (2019) Empagliflozin and dapagliflozin reduce ROS generation and restore NO bioavailability in tumor necrosis factor \u03b1-stimulated human coronary arterial endothelial cells. Cell Physiol Biochem 53:865\u2013886","journal-title":"Cell Physiol Biochem"},{"key":"5214_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.746436","volume":"12","author":"M Vuerich","year":"2021","unstructured":"Vuerich M, Wang N, Kalbasi A, Graham JJ, Longhi MS (2021) Dysfunctional immune regulation in autoimmune hepatitis: from pathogenesis to novel therapies. Front Immunol 12:746436","journal-title":"Front Immunol"},{"key":"5214_CR36","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3748\/wjg.v18.i2.119","volume":"18","author":"HX Wang","year":"2012","unstructured":"Wang HX, Liu M, Weng SY, Li JJ, Xie C, He HL, Guan W, Yuan YS, Gao J (2012) Immune mechanisms of Concanavalin A model of autoimmune hepatitis. World J Gastroenterol 18:119\u2013125","journal-title":"World J Gastroenterol"},{"key":"5214_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/antiox11050799","author":"Y Wang","year":"2022","unstructured":"Wang Y, Ding Y, Sun P, Zhang W, Xin Q, Wang N, Niu Y, Chen Y, Luo J, Lu J, Zhou J, Xu N, Zhang Y, Xie W (2022) Empagliflozin-enhanced antioxidant defense attenuates lipotoxicity and protects hepatocytes by promoting FoxO3a- and Nrf2-mediated nuclear translocation via the CAMKK2\/AMPK pathway. Antioxidants (Basel). https:\/\/doi.org\/10.3390\/antiox11050799","journal-title":"Antioxidants (Basel)"},{"key":"5214_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40139-015-0093-z","volume":"3","author":"YM Yang","year":"2015","unstructured":"Yang YM, Seki E (2015) TNF\u03b1 in liver fibrosis. Curr Pathobiol Rep 3:253\u2013261","journal-title":"Curr Pathobiol Rep"},{"key":"5214_CR39","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.719984","volume":"12","author":"ME Youssef","year":"2021","unstructured":"Youssef ME, Abd El-Fattah EE, Abdelhamid AM, Eissa H, El-Ahwany E, Amin NA, Hetta HF, Mahmoud MH, Batiha GE, Gobba N, Ahmed Gaafar AG, Saber S (2021) Interference with the AMPK\u03b1\/mTOR\/NLRP3 signaling and the IL-23\/IL-17 axis effectively protects against the dextran sulfate sodium intoxication in rats: a new paradigm in empagliflozin and metformin reprofiling for the management of ulcerative colitis. Front Pharmacol 12:719984","journal-title":"Front Pharmacol"},{"key":"5214_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.908037","volume":"9","author":"X Zhan","year":"2022","unstructured":"Zhan X, Cheng L, Huo N, Yu L, Liu C, Liu T, Li G, Fu H (2022) Sodium-glucose cotransporter-2 inhibitor alleviated atrial remodeling in STZ-induced diabetic rats by targeting TLR4 pathway. Front Cardiovasc Med 9:908037","journal-title":"Front Cardiovasc Med"},{"key":"5214_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106137","volume":"80","author":"M Zhang","year":"2020","unstructured":"Zhang M, Li Q, Zhou C, Zhao Y, Li R, Zhang Y (2020) Demethyleneberberine attenuates concanavalin A-induced autoimmune hepatitis in mice through inhibition of NF-\u03baB and MAPK signaling. Int Immunopharmacol 80:106137","journal-title":"Int Immunopharmacol"},{"key":"5214_CR42","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","volume":"15","author":"H Zhou","year":"2018","unstructured":"Zhou H, Wang S, Zhu P, Hu S, Chen Y, Ren J (2018) Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission. Redox Biol 15:335\u2013346","journal-title":"Redox Biol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05214-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05214-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:44:39Z","timestamp":1783907079000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05214-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,11]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5214"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05214-y","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,11]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed in accordance with the guidelines approved by the Mansoura University Animal Care and Use Committee (MU-ACUC), code number (PHARM.R.23.5.22).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}